Equity Overview
Price & Market Data
Price: $0.198
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $308,136,416
Daily Volume: 0
Performance Metrics
1 Week: -2.66%
1 Month: -13.38%
3 Months: -31.18%
6 Months: -18.72%
1 Year: -3.66%
YTD: -13.64%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.